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Introduction
Genetic factors play a substantial role in liability to anorexia nervosa (AN). Relative risk is ~11 in female first-degree relatives of those who have AN (1) , and twin studies estimate heritability at 48%-74% (2) (3) (4) (5) . The Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED) reported the first genome-wide significant locus on chromosome 12 in a region previously implicated in type 1 diabetes and autoimmune illnesses (6) . The goal of the Anorexia Nervosa Genetics Initiative (ANGI) was to rapidly expand available samples for genome-wide association studies (GWAS) of AN. Given the complex genetic architecture of psychiatric disorders, large sample sizes, perhaps hundreds of thousands, are necessary to identify variants associated with these disabling conditions (7, 8) . We provide an overview of recruitment procedures and methods used in ANGI, which collected the largest sample of AN cases and controls in the world, considerably augmenting existing samples in the PGC-ED (9) .
A secondary goal of ANGI was to provide efficient phenotyping for future investigations.
In the absence of biomarkers for psychiatric disorders, the large sample sizes required for GWAS encourage the development of valid assessments with minimal investment of time and effort. Structured clinical interviews, regarded by some as the preferred method for assessing eating disorders (10) , are not economically feasible for such studies. Well-validated and easily accessible self-report assessments provide an alternative and may encourage greater openness about disordered eating behaviors than face-to-face interviews (11, 12) . To this end, we report the validity of an online eating disorder questionnaire (ED100K-v1) designed to capture AN cases and controls for inclusion in ANGI. Data generated from ANGI will provide pertinent Thornton The Anorexia Nervosa Genetics Initiative 5 information about the etiology of AN and contribute to the development of biologically informed therapeutics. deputy director (Thornton); steering committee (chair: Bulik); biological sample committee (chair: Sullivan); analysis group (chair: Sullivan); phenotype group (chair: Thornton); and publication and editorial committee (chair: Bulik). A scientific advisory council provided external oversight of study procedures; monitored progress of sample collection, genotyping, and data analysis; and insured adherence to ethical standards and data sharing procedures. The appropriate ethics or institutional review boards at each location approved study protocols.
Methods and Materials

Collaborative Arrangements
General Study Procedures
In the US, ANZ, and SE, inclusion criteria for cases were based on the Diagnostic and Statistical Manual of Mental Disorders, 4 th edition (DSM-IV) AN Criteria A, B, and C. Amenorrhea Thornton The Anorexia Nervosa Genetics Initiative 6 (Criterion D) was not required since it is not applicable to males and was removed from the DSM-5. In DK, cases were defined as any individual present in the national patient register or who presented in the clinic with an ICD-10 diagnosis of F50.0 (AN) or F50.1 (atypical AN).
Recruitment and study procedures varied across sites (see Figure 1 ) due to local ethical requirements or the manner in which cases were identified and are discussed below.
United States and Australia/New Zealand
Recruitment Approach: A primary focus of our recruitment strategy was to include individuals who: 1) may not live close to recruitment centers, but who desired to participate; 2) may have suffered from AN and never received treatment; 3) have become detached from providers; or 4) are currently in treatment programs. Therefore, we used traditional and novel approaches in the US (ANGI-US) and ANZ [ANGI-ANZ(AUS) and ANGI-ANZ(NZ)]. Recruitment avenues included social and electronic media; eating disorders treatment centers; posts on Recovery Record (a mobile app for individuals in recovery from their eating disorder); prominent eating disorder blogs; and traditional media (e.g., newspaper advertisements and flyers). In the US, ANZ, and SE, television and radio interviews were conducted and website interviews were posted online, which were followed-up on social media sites (e.g., Facebook, Twitter) with links to additional stories. The highly successful Australian media campaign was Thornton The Anorexia Nervosa Genetics Initiative 7 awarded a commendation in the Public Relations Institute of Australia Queensland Awards for Excellence.
Collecting recruitment information regarding how participants heard about the study (US, ANZ) allowed us to evaluate the relative effectiveness of recruitment strategies for costeffective implementation in future genetic and non-genetic research. Furthermore, by recruiting from a wide variety of sources, our sample reflects a broad range of individuals who have had AN and not just those seeking treatment. This is critically important as only 33% of individuals with AN receive treatment for the illness (13, 14) .
Study Procedures:
Individuals who resided in the US (ages ≥12 years), AUS (ages ≥13 years), or NZ (ages ≥14) either self-identified or were referred to the study. In the US, individuals first completed an online screener to determine study eligibility. In all three countries, those who were interested in study participation (and deemed eligible by the brief screen in the US) completed the consent process and online questionnaire based on the Structured Clinical Interview for the DSM-IV (SCID) (15) Module H (eating disorders). Core diagnostic questions from the SCID-Module H were adapted for self-report for ANGI (ED100K-v1) to capture information on lifetime history of eating disorders. Once the questionnaire was completed, the participant provided a blood sample (see DNA Sampling).
Controls assessed for ANGI-US were included in the study if they had no lifetime history of any disordered eating behavior and did not meet any criteria for cases. Additional control samples were obtained from The Price Foundation Study AN Trios Study (16, 17) (19) . Eating disorders are included in the disease checklist: controls with no history of eating disorders were selected. Consent for QSkin allows for inclusion in other research studies. Additional information about recruitment and study procedures from the ANGI-ANZ(AUS) hub is described elsewhere (20) . For ANGI-ANZ(AUS), blood draws occurred in community phlebotomy centers. A prepaid, addressed consignment note for overnight delivery was included. All kits were returned to QIMR for processing. For ANGI-ANZ(NZ), participants across New Zealand first provided witnessed informed consent. They were then sent blood kits which they took to a preferred phlebotomy center where samples were drawn and sent through the national laboratory courier system to Christchurch. Whole blood samples were stored in a tissue bank prior to sending to QIMR to be sent with the ANGI-ANZ(AUS) samples to RUCDR for DNA extraction. supplied by the Lundbeck Initiative for Integrative Psychiatric Research (iPsych) consortium (24) and were genotyped at the same time and on the same platform as those for ANGI-DK. The ANGI-DK(Clinical) DNA samples were extracted from whole blood samples and sent to the Broad for genotyping on the Illumina GSA chip.
Potential controls for participants from New
Validity of the Online Eating Disorder Questionnaire (ED100K-v1)
To assess the validity of the ED100K-v1 questionnaire, we completed follow-up phone interviews using the SCID-Module H with a random subsample of ANGI participants who agreed to recontact from ANGI-US and ANGI-ANZ(AUS). The validity sample included 52 women from the US and 58 women from AUS. Data from one individual from the US was removed from analyses because the highest, not the lowest, weight was reported in the SCID-H. Interviews were conducted by a PhD-level clinician or interviewer with experience administering structured and semi-structured psychiatric diagnostic interviews. All interviewers were trained to SCID criteria by a certified PhD-level clinician from the UNC Assessment Core. Training included reviewing SCID protocol and instructions, observing SCID interviews, reviewing video/audio taped interviews to score, and being observed completing a SCID interview by a PhD-level clinician. Interviewers and the Principal Investigator met regularly for consensus. 1
Statistical Analyses
Statistical analyses were conducted using SAS version 9.3 (30) . We present the percentage of participants who heard about ANGI through each source and temporal data on 1 In Australia, the interviewer reviewed the SCID protocol and instructions, observed SCID interviews, and reviewed existing interviews with staff from the US. Although the interviewer was not observed administering a SCID by a PhD-level clinician in the United States, this individual did have nearly 15 years of experience administering diagnostic interviews, including the SCID.
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The Anorexia Nervosa Genetics Initiative 14 enrollment relative to media launches. We evaluated the extent to which individuals enrolled from clinics differed in lowest illness-related BMI and age at lowest BMI from those in the community, in the US, using t-tests. We examined the construct validity for the online diagnostic questionnaire with the interview-based SCID by calculating the positive and negative predictive values for AN Criteria B and C, and for the presence of binge eating. Higher values correspond to increased accuracy of results. Furthermore, correlations for lowest illness-related BMI and age at low weight were calculated. Results are provided by country. Table 1 provides information regarding the number of cases and controls by site and source. Only those samples that passed quality control to be submitted for genotyping are included.
Results
General ANGI Descriptive Information
---------------------------------------- Insert Table 1 ----------------------------------------
Evaluation of Recruitment Sources
Details about where participants heard about ANGI in the US are provided in Figure 2 .
The most successful recruitment avenue for cases was the Internet, including social media, whereas, for controls, it was email followed by the Internet. Advocacy groups and clinicians (including clinical programs and eating disorder centers) were also important for recruiting Thornton The Anorexia Nervosa Genetics Initiative 15 cases. More than 20% of controls heard about ANGI through ResearchMatch (a not-for-profit online recruitment tool) or UNC (but not via email). Notably, 12% of cases and 13% of controls heard about ANGI from family members. Similarly, Figure 4 illustrates the impact of media launches for ANGI-ANZ(NZ) recruitment.
We also explored whether cases from eating disorder treatment centers were significantly more ill than individuals from the community in the US. Cases ascertained through the community reported a significantly younger age at lowest weight [mean(sd)=17.4 (5.7)] than those recruited through eating disorders clinics [mean(sd)=19.5 (9.9)]. The two groups also differed significantly in lowest BMI with those from eating disorders clinics [mean(sd)=14.2 (2.1)], having lower BMIs than those from the community [mean(sd)=15.1 (1.9)]. However, the majority of participants in both groups, 82.8% from eating disorder clinics and 63.3% from the Thornton The Anorexia Nervosa Genetics Initiative 16 community, reported illness-related BMI values consistent with severe and extreme DSM-5 AN severity indices. Table 2 lists the construct validity results. Positive predictive values were high in both countries, indicating that among those who had a positive screening test, the probability of AN Criterion B, Criterion C, and binge eating ranged from 85% to 100%. Results also indicated that among women who had a negative screening test, the probability of not having these AN criteria or binge eating was between 77% and 100%. For AUS, all participants endorsed Criterion C in the ED100K-v1 questionnaire and all but one individual endorsed Criterion C in the interview; thus, we could not calculate negative predictive value.
Validity of Online Eating Disorder Questionnaire
The correlations between the ED100K-v1 questionnaire and interview responses for lowest illness-related BMI were high (US: r=0.91; AUS: r=0.92). The correlation for age at lowest weight in the US (r=0.58) was lower than that for AUS (r=0.90). In the US, the mean (SD) difference for age at lowest weight between the questionnaire and interview was 7.0 (10.7) years; three individuals reported a lower lifetime weight occurring between the self-report questionnaire and interview. Table 2 Discussion The primary goal of ANGI was to inform the etiology of AN by amassing the largest genetic sample of AN ever assembled and creating data and sample resources for future research. To accomplish this, we combined new and existing resources from the US, ANZ, SE, and DK. Although methods varied across countries, we were successful in ascertaining broadly representative cases and controls.
Our approaches optimized resources in each country. The existence of national patient registers (SE and DK) and quality registers (SE) facilitated identification of individuals who had been treated for AN (cases) as well as controls. The carefully curated biobank of PKU cards in DK made for a highly efficient ascertainment strategy, but precluded re-contacting participants for future research. The ability to link both the Swedish and Danish data to other national registers will allow us to expand analyses to include a broad range of phenotypes and exposures and even design gene-by-environment interaction investigations that include measured genotypes.
The majority of both clinic-and community-ascertained cases had illness-related BMIs in the DSM-5 severe and extreme ranges. However, those recruited via clinics reported older ages at low weight and somewhat lower illness-related BMIs than cases from the community.
Notably, some cases from the community reported lowest BMI values that were lower than the range observed for those from the clinic. These observations are encouraging for general community recruitment for psychiatric genetics-at least for disorders in which there is strong social media presence. Although the percentage of individuals recruited via social media who Thornton The Anorexia Nervosa Genetics Initiative 18 had not received treatment is unknown, it raises ongoing concerns that many individuals with AN are distanced from clinical providers and not receiving care for their illness (13, 14, 31) .
We were also able to provide information on the appropriateness of using a web-based diagnostic questionnaire for ascertainment of cases. ED100K-v1 operationalizes the DSM-IV criteria for all eating disorders (now adapted for DSM-5). The questionnaire was comparable to the SCID eating disorders module in determining the presence of criteria B and C for AN and in assessing lowest illness-related BMI and age at low weight in both the US and AUS. Given the need for large samples for successful GWAS, efficient case identification and minimally adequate phenotyping are methodologically important (7) . A self-report questionnaire based on a structured interview that accurately identifies cases reduces the time and money spent on clinical interviewing and streamlines the case identification and ascertainment process.
ANGI does have limitations. First, ANGI participants are primarily of European ancestry.
As yet, it is unclear whether psychiatric disorder GWAS findings can be generalized across populations (32) . Second, AN primarily afflicts females. The small number of males recruited limits our capacity to determine sex differences in genetic effects. Future studies will require targeted strategies to ascertain and recruit substantial numbers of males. Third, ANGI used several ascertainment strategies to maximize recruitment in the shortest possible time. This could have led to the different sets of cases having different genetic architectures. However, the experience of the PGC (and other groups) provides strong evidence that, if this is true, the adverse impact is small relative to the large benefits of an increased sample (7, 33) . Finally, the SE and DK collections enable linkage with other national registers that can provide a Thornton The Anorexia Nervosa Genetics Initiative 19 comprehensive characterization of psychiatric and somatic comorbidity, whereas these auxiliary data are not available in the US and ANZ.
In summary, the ability to generate large sample sizes for genomic investigations on eating disorders and other psychiatric disorders requires multi-site and international collaborations, as has been successfully demonstrated with the Wellcome Trust Case Control Consortium (34) and the PGC (6) . The ANGI data are undergoing rigorous quality control and are being meta-analyzed with existing PGC-ED data. The combined sample size is approaching 20,000 cases with ancestrally matched controls, which should yield additional genome-wide signals.
Given the high prevalence of comorbid psychopathology in AN and eating disorders more broadly (13, 35, 36) , these data can also be used for cross-disorder meta-analyses and SNP-based genetic correlations to identify putative genetic variants shared with other psychiatric and genetically influenced phenotypes. Moreover, an accurate and cost-efficient approach to case and control identification through self-report online questionnaires or existing national patient registers demonstrated here, is critical for rapid sample acquisition. Although ANGI was a highly successful collaboration, even larger sample sizes must be obtained to maximize GWAS findings. Ongoing collections from Europe and Asia are queued for genotyping, and large collections for other eating disorders (bulimia nervosa and binge-eating disorder) are underway. The PGC blueprint for the future aims for 100,000 cases for all major disorders is a scientifically justifiable aim (8) . Uncovering the biological basis of eating disorders will aid in our understanding of their etiology, contribute to the development of novel or repurposed therapeutics, and ultimately reduce disability and mortality associated with the illnesses.
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